FDA approves mRNA flu vaccine for older adults

@pbsnews

3.2M followers · usually 15.6K views a post

Views

149.4K

Likes

5.1K

Comments

3.3K

Shares

3.3K

Promoted product

MFLUSIVA

Deliver the greatest possible impact to people through mRNA medicines.

2 videos2 creators

Why it worked

The video leverages a timely and relevant health news topic, the approval of a new vaccine, to inform viewers. The use of clear on-screen text and a concise narrative makes the information easily digestible, appealing to a broad audience interested in health and medical advancements.

Summary

The FDA has approved Moderna's mFlusiva, an mRNA flu vaccine for adults aged 50-64, utilizing the same technology as the COVID-19 vaccine. This new vaccine is quicker to manufacture than traditional ones and is expected to offer better protection against emerging flu strains.

Free account

Transcript, structure and on-screen text

5 beats, a 91-word transcript and 14 lines of on-screen text — the parts you need to write your own version.

Original caption

The same mRNA technology that made the COVID-19 vaccine possible will soon be used in flu vaccines for older Americans. The FDA has approved a new shot from Moderna called mFlusiva for adults age 50 to 64. The company is also seeking full approval for adults 65 and older. Compared to traditional shots, mRNA vaccines are quicker to manufacture. Experts say that could help protect against future strains of the flu as they emerge. The FDA had initially refused to consider Moderna's application amid the Trump administration's heightened scrutiny of vaccines. #pbsnewshour #newshour #pbsnews #news #trumpadministration #fda #mrna #fluseason #flushot #moderna